Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACRV Acrivon Therapeutics	$1.10	$1.60	$1.06 ▼ $10.16	$34.49M	1.88	231,865 shs	665,213 shs
AKBA Akebia Therapeutics	$3.01 +4.5%	$2.23	$0.80 ▼ $3.14	$790.53M	0.88	2.92 million shs	7.55 million shs
GRCL Gracell Biotechnologies	$10.25	$10.25	$1.40 ▼ $10.44	$744.95M	-0.33	1.32 million shs	N/A
INZY Inozyme Pharma	$3.95 -0.3%	$1.62	$0.72 ▼ $6.24	$255.02M	1.35	852,707 shs	3.82 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACRV Acrivon Therapeutics	0.00%	-4.35%	-23.61%	-79.28%	-85.33%
AKBA Akebia Therapeutics	+4.51%	+6.36%	+23.87%	+62.70%	+192.23%
GRCL Gracell Biotechnologies	0.00%	0.00%	0.00%	0.00%	0.00%
INZY Inozyme Pharma	0.00%	-0.25%	+272.64%	+229.17%	-12.42%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACRV Acrivon Therapeutics	3.6791 of 5 stars	4.5	3.0	0.0	0.0	2.2	3.3	0.6
AKBA Akebia Therapeutics	4.1376 of 5 stars	4.6	1.0	0.0	4.0	3.1	0.0	0.6
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	3.3001 of 5 stars	4.2	3.0	0.0	0.0	3.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACRV Acrivon Therapeutics	3.00	Buy	$17.71	1,510.39% Upside
AKBA Akebia Therapeutics	3.20	Buy	$6.63	120.10% Upside
GRCL Gracell Biotechnologies	0.00	N/A	N/A	N/A
INZY Inozyme Pharma	2.44	Hold	$11.75	197.47% Upside

Current Analyst Ratings Breakdown

Latest AKBA, INZY, ACRV, and GRCL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ACRV Acrivon Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/15/2025	ACRV Acrivon Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$10.00 ➝ $9.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/5/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$6.00
5/4/2025	ACRV Acrivon Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/28/2025	AKBA Akebia Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	$5.38 per share	N/A
AKBA Akebia Therapeutics	$184.91M	4.28	N/A	N/A	($0.16) per share	-18.81
GRCL Gracell Biotechnologies	$60K	12,415.83	N/A	N/A	$2.95 per share	3.47
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$2.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACRV Acrivon Therapeutics	-$60.39M	-$2.22	N/A	N/A	N/A	N/A	-47.95%	-43.73%	8/12/2025 (Estimated)
AKBA Akebia Therapeutics	-$51.92M	-$0.21	N/A	N/A	N/A	-27.07%	N/A	-20.57%	8/14/2025 (Estimated)
GRCL Gracell Biotechnologies	-$88.08M	-$1.05	N/A	N/A	N/A	N/A	-37.40%	-31.24%	N/A
INZY Inozyme Pharma	-$71.17M	-$1.69	N/A	N/A	N/A	N/A	-88.42%	-57.02%	8/5/2025 (Estimated)

Latest AKBA, INZY, ACRV, and GRCL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/13/2025	Q1 2025	ACRV Acrivon Therapeutics	-$0.57	-$0.51	+$0.06	-$0.51	N/A	N/A
5/8/2025	Q1 2025	AKBA Akebia Therapeutics	-$0.03	$0.03	+$0.06	$0.03	$44.88 million	$57.34 million
3/27/2025	Q4 2024	ACRV Acrivon Therapeutics	-$0.69	-$0.60	+$0.09	-$0.60	N/A	N/A
3/13/2025	Q4 2024	AKBA Akebia Therapeutics	-$0.05	-$0.10	-$0.05	-$0.10	$37.36 million	$46.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACRV Acrivon Therapeutics	N/A	N/A	N/A	N/A	N/A
AKBA Akebia Therapeutics	N/A	N/A	N/A	N/A	N/A
GRCL Gracell Biotechnologies	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACRV Acrivon Therapeutics	N/A	12.75	12.75
AKBA Akebia Therapeutics	N/A	1.52	1.21
GRCL Gracell Biotechnologies	0.02	7.73	7.73
INZY Inozyme Pharma	0.51	7.68	7.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACRV Acrivon Therapeutics	71.62%
AKBA Akebia Therapeutics	33.92%
GRCL Gracell Biotechnologies	N/A
INZY Inozyme Pharma	88.30%

Insider Ownership

Company	Insider Ownership
ACRV Acrivon Therapeutics	11.90%
AKBA Akebia Therapeutics	3.00%
GRCL Gracell Biotechnologies	28.00%
INZY Inozyme Pharma	12.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACRV Acrivon Therapeutics	58	31.36 million	28.49 million	Not Optionable
AKBA Akebia Therapeutics	430	262.64 million	209.24 million	Optionable
GRCL Gracell Biotechnologies	314	72.68 million	52.33 million	Optionable
INZY Inozyme Pharma	50	64.56 million	57.05 million	Optionable

AKBA, INZY, ACRV, and GRCL Headlines

Recent News About These Companies

Millennium Management LLC Has $5.21 Million Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)

May 30 at 3:36 AM | marketbeat.com

BMRN to Acquire Inozyme Pharma

May 22, 2025 | finance.yahoo.com

INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY

May 21, 2025 | businesswire.com

Jacobs Levy Equity Management Inc. Takes Position in Inozyme Pharma, Inc. (NASDAQ:INZY)

May 20, 2025 | marketbeat.com

Cubist Systematic Strategies LLC Acquires New Stake in Inozyme Pharma, Inc. (NASDAQ:INZY)

May 20, 2025 | marketbeat.com

443,255 Shares in Inozyme Pharma, Inc. (NASDAQ:INZY) Acquired by Sanofi

May 19, 2025 | marketbeat.com

Inozyme Pharma (NASDAQ:INZY) Stock Rating Lowered by Needham & Company LLC

May 19, 2025 | marketbeat.com

Inozyme Pharma (NASDAQ:INZY) Downgraded to "Hold" Rating by Wedbush

May 19, 2025 | marketbeat.com

StockWatch: With Inozyme Buyout, BioMarin Pursues Growth via M&A

May 18, 2025 | genengnews.com

Jefferies Downgrades Inozyme Pharma (INZY)

May 17, 2025 | msn.com

Needham Downgrades Inozyme Pharma (INZY)

May 17, 2025 | msn.com

Leerink bullish on BioMarin following Inozyme deal, expects additional BD

May 17, 2025 | finance.yahoo.com

Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages

May 17, 2025 | marketbeat.com

Inozyme Shares More Than Double in Surge Toward BioMarin's Buyout Price

May 16, 2025 | marketwatch.com

BioMarin to buy rare disease drugmaker Inozyme for $270M

May 16, 2025 | biopharmadive.com

BioMarin stock rises following Inozyme Pharma acquisition

May 16, 2025 | in.investing.com

BioMarin to Acquire Inozyme Pharma for $270M

May 16, 2025 | contractpharma.com

BioMarin buys Inozyme for $270 million

May 16, 2025 | thepharmaletter.com

BioMarin to buy enzyme therapy developer Inozyme in $270M all-cash deal

May 16, 2025 | msn.com

Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens

May 16, 2025 | msn.com

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Inozyme Pharma, Inc. - INZY

May 16, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA, INZY, ACRV, and GRCL Company Descriptions

Acrivon Therapeutics NASDAQ:ACRV

$1.10 0.00 (0.00%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$1.12 +0.02 (+1.91%)

As of 08:17 AM Eastern

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. The company is also developing its preclinical stage pipeline programs targeting critical nodes in the DNA damage response, or DDR, pathways; and ACR-2316, a dual WEE1/PKMYT1 inhibitor. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.

Akebia Therapeutics NASDAQ:AKBA

$3.01 +0.13 (+4.51%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$3.08 +0.07 (+2.33%)

As of 08:27 AM Eastern

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Gracell Biotechnologies NASDAQ:GRCL

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in phase 1 clinical trial for the treatment of relapsed or refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL) in adult; and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 2 clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as hematologic cell malignancies and solid tumors. Gracell Biotechnologies Inc. was incorporated in 2017 and is headquartered in Suzhou, China. As of February 22, 2024, Gracell Biotechnologies Inc. operates as a subsidiary of AstraZeneca Treasury Limited.

Inozyme Pharma NASDAQ:INZY

$3.95 -0.01 (-0.25%)

Closing price 05/29/2025 04:00 PM Eastern

Extended Trading

$3.96 +0.00 (+0.13%)

As of 08:26 AM Eastern

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time